RAD51AP1 as an Immune-Related Prognostic Biomarker and Therapeutic Response Predictor in Hepatocellular Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.CAN-14-0155
   PubMed Web of Science ®Google Scholar
• Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61–74. doi:10.1055/s-0030-1247133
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: current and future perspectives. Hepat Oncol. 2017;4(4):111–122. doi:10.2217/hep-2017-0019
   PubMedGoogle Scholar
• Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009;9(6):739–745. doi:10.1586/era.09.41
   PubMed Web of Science ®Google Scholar
• Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434(7035):864–870. doi:10.1038/nature03482
   PubMed Web of Science ®Google Scholar
• Donne R, Saroul-Ainama M, Cordier P, et al. Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD. Developmental Cell. 2022;57(14):1728–1741.e1726. doi:10.1016/j.devcel.2022.06.003
   PubMed Web of Science ®Google Scholar
• Ahodantin J, Bou-Nader M, Cordier C, et al. Hepatitis B virus X protein promotes DNA damage propagation through disruption of liver polyploidization and enhances hepatocellular carcinoma initiation. Oncogene. 2019;38(14):2645–2657. doi:10.1038/s41388-018-0607-3
   PubMed Web of Science ®Google Scholar
• Kovalenko OV, Golub EI, Bray-Ward P, Ward DC, Radding CM. A novel nucleic acid-binding protein that interacts with human rad51 recombinase. Nucleic Acids Res. 1997;25(24):4946–4953. doi:10.1093/nar/25.24.4946
   PubMed Web of Science ®Google Scholar
• Mizuta R, LaSalle JM, Cheng HL, et al. RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. Proc Natl Acad Sci USA. 1997;94(13):6927–6932. doi:10.1073/pnas.94.13.6927
   PubMed Web of Science ®Google Scholar
• Modesti M, Budzowska M, Baldeyron C, Demmers JA, Ghirlando R, Kanaar R. RAD51AP1 is a structure-specific DNA binding protein that stimulates joint molecule formation during RAD51-mediated homologous recombination. Mol Cell. 2007;28(3):468–481. doi:10.1016/j.molcel.2007.08.025
   PubMed Web of Science ®Google Scholar
• Zhao H, Gao Y, Chen Q, et al. RAD51AP1 promotes progression of ovarian cancer via TGF-β/Smad signalling pathway. J Cell Mol Med. 2021;25(4):1927–1938. doi:10.1111/jcmm.15877
   PubMed Web of Science ®Google Scholar
• Zheng L, Li L, Xie J, Jin H, Zhu N. Six novel biomarkers for diagnosis and prognosis of esophageal squamous cell carcinoma: validated by scRNA-seq and qPCR. J Cancer. 2021;12(3):899–911. doi:10.7150/jca.50443
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang H, Qiao L, Jin X, Dong H, Wang Y. Silencing of RAD51AP1 suppresses epithelial-mesenchymal transition and metastasis in non-small cell lung cancer. Thorac Cancer. 2019;10(9):1748–1763. doi:10.1111/1759-7714.13124
   PubMed Web of Science ®Google Scholar
• Obama K, Satoh S, Hamamoto R, Sakai Y, Nakamura Y, Furukawa Y. Enhanced expression of RAD51 associating protein-1 is involved in the growth of intrahepatic cholangiocarcinoma cells. Clin Cancer Res. 2008;14(5):1333–1339. doi:10.1158/1078-0432.CCR-07-1381
   PubMed Web of Science ®Google Scholar
• Xie S, Jiang X, Zhang J, et al. Identification of significant gene and pathways involved in HBV-related hepatocellular carcinoma by bioinformatics analysis. PeerJ. 2019;7:e7408. doi:10.7717/peerj.7408
   PubMed Web of Science ®Google Scholar
• Zhuang L, Zhang Y, Meng Z, Yang Z. Oncogenic roles of RAD51AP1 in tumor tissues related to overall survival and disease-free survival in hepatocellular carcinoma. Cancer Control. 2020;27(1):1073274820977149. doi:10.1177/1073274820977149
   Web of Science ®Google Scholar
• Wickham HCW, Henry L, Pedersen T, et al. ggplot2: create elegant data visualisations using the grammar of graphics. R package version 3.4.3; 2023. Available from: https://CRAN.R-project.org/package=ggplot2. Accessed September 22, 2023.
   Google Scholar
• FEHJ. RMS: regression modeling strategies. R package version 6.7-0; 2023. Available from: https://CRAN.R-project.org/package=rms. Accessed September 22, 2023.
   Google Scholar
• TMT. Survival: survival analysis. R package version 3.5-7; 2023. Available from: https://CRAN.R-project.org/package=survival. Accessed September 22, 2023.
   Google Scholar
• Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics. 2007;23(23):3251–3253. doi:10.1093/bioinformatics/btm369
   PubMed Web of Science ®Google Scholar
• Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS J Integr Biol. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Meth. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucl Acids Res. 2020;48(W1):W509–w514. doi:10.1093/nar/gkaa407
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014;9(9):e107468. doi:10.1371/journal.pone.0107468
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019
   PubMed Web of Science ®Google Scholar
• Wang X, Liao X, Yu T, et al. Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma. Int J Oncol. 2019;55(4):805–822. doi:10.3892/ijo.2019.4862
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905. doi:10.1038/nature08822
   PubMed Web of Science ®Google Scholar
• Rao CV, Asch AS, Yamada HY. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis. 2017;38(1):2–11. doi:10.1093/carcin/bgw118
   PubMed Web of Science ®Google Scholar
• Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen. 2017;58(5):235–263. doi:10.1002/em.22087
   PubMed Web of Science ®Google Scholar
• Wright WD, Shah SS, Heyer WD. Homologous recombination and the repair of DNA double-strand breaks. J Biol Chem. 2018;293(27):10524–10535. doi:10.1074/jbc.TM118.000372
   PubMed Web of Science ®Google Scholar
• Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008;18(1):99–113. doi:10.1038/cr.2008.1
   PubMed Web of Science ®Google Scholar
• Richardson C. RAD51, genomic stability, and tumorigenesis. Cancer Lett. 2005;218(2):127–139. doi:10.1016/j.canlet.2004.08.009
   PubMed Web of Science ®Google Scholar
• Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010;11(3):196–207. doi:10.1038/nrm2851
   PubMed Web of Science ®Google Scholar
• Pires E, Sung P, Wiese C. Role of RAD51AP1 in homologous recombination DNA repair and carcinogenesis. DNA Repair. 2017;59:76–81. doi:10.1016/j.dnarep.2017.09.008
   PubMed Web of Science ®Google Scholar
• Wiese C, Dray E, Groesser T, et al. Promotion of homologous recombination and genomic stability by RAD51AP1 via RAD51 recombinase enhancement. Mol Cell. 2007;28(3):482–490. doi:10.1016/j.molcel.2007.08.027
   PubMed Web of Science ®Google Scholar
• Barroso-Gonzalez J, Garcia-Exposito L, Hoang SM, et al. RAD51AP1 is an essential mediator of alternative lengthening of telomeres. Mol Cell. 2020;79(2):359. doi:10.1016/j.molcel.2020.06.026
   PubMed Web of Science ®Google Scholar
• Bridges AE, Ramachandran S, Pathania R, et al. RAD51AP1 deficiency reduces tumor growth by targeting stem cell self-renewal. Cancer Res. 2020;80(18):3855–3866. doi:10.1158/0008-5472.CAN-19-3713
   PubMed Web of Science ®Google Scholar
• Wang Q, Tan Y, Fang C, et al. Single-cell RNA-seq reveals RAD51AP1 as a potent mediator of EGFRvIII in human glioblastomas. Aging. 2019;11(18):7707–7722. doi:10.18632/aging.102282
   PubMedGoogle Scholar
• Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res. 2021;27(4):1003–1011. doi:10.1158/1078-0432.Ccr-20-2571
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309–5337. doi:10.1016/j.cell.2021.09.020
   PubMed Web of Science ®Google Scholar
• Ding L, Zhang E, Yang Q, et al. Vertical sleeve gastrectomy confers metabolic improvements by reducing intestinal bile acids and lipid absorption in mice. Proceed Nat Acad Sci Unit State Am. 2021;118:6. doi:10.1073/pnas.2019388118
   Web of Science ®Google Scholar
• Li C, Xu X, Wei S, Jiang P, Xue L, Wang J. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunother Cancer. 2021;9(1):e001341. doi:10.1136/jitc-2020-001341
   PubMed Web of Science ®Google Scholar
• Bridges AE, Ramachandran S, Tamizhmani K, et al. RAD51AP1 loss attenuates colorectal cancer stem cell renewal and sensitizes to chemotherapy. Mol Cancer Res. 2021;19(9):1486–1497. doi:10.1158/1541-7786.Mcr-20-0780
   PubMed Web of Science ®Google Scholar